Gossamer Bio Revenue and Competitors

Claim your profile

Location

$480M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Gossamer Bio's estimated annual revenue is currently $6M per year.(i)
  • Gossamer Bio received $230.0M in venture funding in July 2018.
  • Gossamer Bio's estimated revenue per employee is $25,723
  • Gossamer Bio's total funding is $480M.
  • Gossamer Bio's current valuation is $906.1M. (January 2022)

Employee Data

  • Gossamer Bio has 235 Employees.(i)
  • Gossamer Bio grew their employee count by -6% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.7M619%$53MN/A
#2
$34.3M17717%$110MN/A
#3
$0.4M2735%$236.7MN/A
#4
$34.5M178-5%$160MN/A
#5
$3.7M2420%N/AN/A
#6
$147.3M3212%$192.5MN/A
#7
$17.5M113-3%$24.1MN/A
#8
$2.7M4379%N/AN/A
#9
$34.1M220100%N/AN/A
#10
$47.1M304-3%N/AN/A

Gossamer Bio is a San Diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. Founded by the former Receptos executive team, Gossamer Bio's strategy will be to leverage an asset-rich in-licensing environment, with a focus on areas of high unmet need, utilizing a team with a strong track record of execution in immunology, inflammation, fibrosis and oncology.

keywords:N/A

$480M

Total Funding

235

Number of Employees

$6M

Revenue (est)

-6%

Employee Growth %

$906.1M

Valuation

N/A

Accelerator

Gossamer Bio News

2022-04-17 - Gossamer Bio, Inc. (NASDAQ:GOSS) Receives Consensus ...

Gossamer Bio, Inc. (NASDAQ:GOSS) Receives Consensus Rating of “Buy” from Analysts. Posted by admin on Apr 17th, 2022.

2022-04-17 - Gossamer Bio (NASDAQ:GOSS) Receives New Coverage ...

Other analysts have also issued reports about the company. Sumitomo Mitsui Financial Group upgraded Gossamer Bio from a “neutral” rating to an “...

2022-04-06 - Gossamer Bio stock rises 8% as UBS initiates with Buy on ...

Gossamer Bio [[GOSS, +8%]] was initiated with a Buy at UBS with a price target of $19. UBS said it thinks Gossamer's (NASDAQ:GOSS) clinical...

2021-02-25 - Gossamer Bio Announces Fourth Quarter and Full-Year 2020 Financial Results and Provides Business Update

SAN DIEGO--(BUSINESS WIRE)--Feb 25, 2021-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial re ...

2019-09-08 - Gossamer Bio Inc (NASDAQ:GOSS) Shares Sold by Artal ...

Artal Group S.A. trimmed its position in Gossamer Bio Inc (NASDAQ:GOSS) by 3.0% in the 2nd quarter, according to the company in its most ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$53.2M2361%N/A
#2
$46.9M23741%N/A
#3
N/A2372%N/A
#4
$64.4M23813%N/A
#5
$37M239-4%N/A

Gossamer Bio Funding

DateAmountRoundLead InvestorsReference
2018-01-08$100.0MUndisclosedOmega FundsArticle
2018-07-24$230.0MHillhouse CapitalArticle